Overview

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Status:
Completed
Trial end date:
2020-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
Phase:
Phase 2
Details
Lead Sponsor:
InflaRx GmbH
Collaborator:
Quintiles, Inc.
Treatments:
Vilobelimab